Generally PPI overuse is worrisome because of its possible adverse events. The consensus for their use indicates that they should be used in the appropriate doses during the required time while we await prospective studies that will allow us to explain whether or not PPIs play a role in these events 13. 3. Feldman M. Gastric secretion En Feldman: Sleisenger and Fordtrans. Gastrointestinal and liver disease. WB Saunders company Philadelphia; 2006. 4. Del Valle J, Todisco A. Gastric secretion. En Yamada T, Alpers DH, Kaplowitz N, Laines L, Owyang C, Powell DW, Eds. Textbook of Gastroenterology 4th Edition. Philadelphia: Lippincott William and Williams 2003. p. 266-307. 5. AS Giraud, C Jackson, TR Memheniott, LM Judd. Differentiation of the gastric mucosa IV: Role of trefoil peptides and I.L.-6 cytokine family signaling in gastric homeostasis. Am J Physiol Gastrointest liver Physiol 2007; 292: G1-G5. 6. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease and stress erosive syndrome Gastroenterology 2000; 118: S9. 7. Hattlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and breakthrough on different regimen of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235-1240. 8. Peghini PL, Katz PO, Castell DO. Ranitidine control nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-39. 9. Katz PO, Anderson R Khoury, Castell DO. Gastro oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitor. Aliment Pharmacol Ther 1998; 12: 1231-1234. 10. Hammer J, Schmidt B. Effect of splitting dose of omeprazole on gastric acidity and nocturnal acid Breakthrough. Aliment Pharmacol Ther 2005; 22: 129-134. 11. Katz PO. Review article: Putting immediate release proton pump inhibitors into clinical practice improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. Aliment Pharmacol Thera 2005; 22Suppl 3 32-38. 12. Rackoff A, Agrawal A, Hila I, et al. Histamine 2 receptor antagonist at night improve G.E.R.D. symptoms for patients on PPI therapy. Dis Esophagus 2005; 18: 370. 13. Fackler WK, Our TM, Vaezy MF, et al. Long term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-632. 15. Katz PO, Scheiman J M, Barkun AN. Review article: Acid related disease-What are the unmet clinical needs? Aliment Pharmacol Ther 2006; 23supp.2: 9-22. 16. Mc Quaidi KR, Laine L. Early heartburn relief with PPI: A systematic review and meta-analysis of clinical trial. Clin Gastroenterol Hepato 2005; 3: 553. 17. Carmack S, Genta R, Schul C, Saboorian H. The current spectrum of gastric polyps: A one year national study of over 120.000 patients. Am J Gastroenterol 2009; 104: 1524-1532. 18. Wang J, Varro A, Lightdale C, et al. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrets esophagus Am J Gastroenterol Advance on line publication 10 nov 2009; doi: 10.1038/ajg 2009.629
En general, la sobreutilización de IBP es preocupante por sus posibles eventos adversos y el consenso para su uso indica que las dosis deben ser adecuadas por el tiempo requerido mientras se esperan estudios prospectivos que permitan dilucidar si los IBP intervienen o no en estos eventos 13.